Mechanisms of androgen-refractory prostate cancer.
Department of Urology, Mayo Clinic College of Medicine, Rochester, Minn, USA.
Jose D
JD
Debes
Donald J
DJ
Tindall
D000728:Androgens / Q000378:metabolism; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D017209:Apoptosis; D000077143:Docetaxel; D019008:Drug Resistance, Neoplasm / Q000502:physiology; D005784:Gene Amplification; D006801:Humans; D008297:Male; D009154:Mutation; D009376:Neoplasms, Hormone-Dependent / Q000378:metabolism*; D011471:Prostatic Neoplasms / Q000188:drug therapy / Q000378:metabolism*; D011944:Receptors, Androgen / Q000235:genetics / Q000378:metabolism*; D015398:Signal Transduction; D043823:Taxoids / Q000008:administration & dosage
D000728:Androgens; D011944:Receptors, Androgen; D043823:Taxoids; D000077143:Docetaxel